



Carbapenem-Resistant Enterobacterales: Development of New Antibiotics

Guest Editor:

Dr. Paolo Gaibani
IRCCS Azienda-Ospedaliera,
Universitaria di Bologna,
Bologna, Italy

Deadline for manuscript
submissions:
closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

Carbapenem-resistant Enterobacteriaceae (CRE) represents a serious threat for public health and a challenge for clinicians. CRE are often resistant to multiple antimicrobials and antimicrobial options available against these microorganisms are limited. Recently, novel β -lactams/ β -lactamase inhibitor combinations (β L- β LICs) have been developed for the treatment of DTR infections resulting from CRE pathogens. These novel molecules represent a promising tool to counteract CRE infections and limit diffusion of MDR microorganisms. This Special Issue is dedicated to research on novel antimicrobials against CRE, including novel approaches to optimizing antimicrobial treatments, characterization of new traits of resistance and the epidemiology of susceptibility patterns.

Dr. Paolo Gaibani
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi